FDA Recommends Genetic Testing For Plavix, Opens Window For Effient

FDA's latest revision to Plavix labeling on the issue of poor response in slow metabolizers has heightened the concerns to the highest level - that of a "black box" warning - and recommends use of testing to identify genetic differences in patients' metabolizing function. But FDA officials note that the testing won't be practical in all treatment settings - which leaves another opening for Lilly/Daiichi Sankyo to push use of their competitor Effient